Northwest Biotherapeutics (OTCMKTS:NWBO) Share Price Crosses Below 200 Day Moving Average – Time to Sell?

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO)’s stock price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.21 and traded as low as $0.1631. Northwest Biotherapeutics shares last traded at $0.1696, with a volume of 3,194,485 shares traded.

Northwest Biotherapeutics Trading Down 1.0%

The firm has a market capitalization of $286.30 million, a P/E ratio of -0.01 and a beta of -0.60. The stock has a 50 day simple moving average of $0.18 and a 200-day simple moving average of $0.21.

Northwest Biotherapeutics (OTCMKTS:NWBO) last issued its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($0.01) earnings per share for the quarter. The firm had revenue of $0.81 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Northwest Biotherapeutics stock. Compass Financial Management LLC acquired a new stake in shares of Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 1,215,500 shares of the biotechnology company’s stock, valued at approximately $227,000. Compass Financial Management LLC owned 0.07% of Northwest Biotherapeutics at the end of the most recent reporting period. Institutional investors own 0.04% of the company’s stock.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.

The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.